AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Edward Boghosian who wrote (1662)	11/15/1999 9:31:00 PM
From: arnie h	Read Replies (2) of 2173

Ed: <"statistically significant decrease" is not the same as significant decrease. I would like to see whole numbers instead of 0.7 and 0.4.> I'm not sure just what your concern is since the FDA requires a statistically significant decrease (vs. a decrease that is not statistically significant). In this trial, the probabilities were quite good for significance unlike the prior trial where p>.05 as needed. In this trial it was p=.015 so plenty of safety margin. As far as whole numbers, that would be astonishing for this disease. The impressive result is that the 12 month result was better than for the 6 months showing no fade in efficacy. Also, patients apparently used less insulin and showed good weight control. All in all, a pretty good result. Regards, Arnie

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next